Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease

//Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease

Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease

P.I.: Karen S. Servilla, MD, FACP                                                                                         

Synopsis – Testing the new medication, vadadustat to determine if it is an effective maintenance treatment for anemia (low red blood cell count) in patients with chronic (long-term) kidney disease.

2017-10-23T19:00:04+00:00October 23rd, 2017|Categories: Clinical Trials|